The Wilms’ tumor (WT1) gene expression correlates with the International Prognostic Scoring System (IPSS) score in patients with myelofibrosis and it is a marker of response to therapy

Daniela Gallo, Paolo Nicoli, Chiara Calabrese, Valentina Gaidano, Jessica Petiti, Valentina Rosso, Elisabetta Signorino, Sonia Carturan, Giada Bot-Sartor, Gisella Volpe, Francesco Frassoni, Giuseppe Saglio, Daniela Cilloni

Research output: Contribution to journalComment/debate

3 Citations (Scopus)

Abstract

The Wilms tumor gene WT1 is a useful marker of clonal hematopoiesis and it has been shown to be a good marker of residual disease and it reflects the response to therapy. Although myelofibrosis is characterized by mutations of JAK2 and calreticulin (CALR), these mutations are not useful to monitor response to therapy. In this study we demonstrated that in patients affected by myelofibrosis WT1 correlates with the International Prognostic Scoring System (IPSS) score at diagnosis. Furthermore WT1 is a good marker of response to JAK2 inhibitors especially for patients without blasts and for patients who develop anemia or thrombocytopenia not for progression but as therapy related toxicity. Finally, WT1 transcript reduction can mirror a benefit of therapy on the disease burden. This study demonstrated that WT1 is a good marker for monitoring the response to therapy in patients affected by myelofibrosis.

Original languageEnglish
Pages (from-to)1650-1653
Number of pages4
JournalCancer Medicine
Volume5
Issue number7
DOIs
Publication statusPublished - Jul 1 2016

Fingerprint

Wilms' Tumor Genes
Primary Myelofibrosis
Gene Expression
Calreticulin
Therapeutics
Mutation
Hematopoiesis
Thrombocytopenia
Anemia

Keywords

  • JAK2
  • molecular marker
  • myelofibrosis
  • WT1

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

The Wilms’ tumor (WT1) gene expression correlates with the International Prognostic Scoring System (IPSS) score in patients with myelofibrosis and it is a marker of response to therapy. / Gallo, Daniela; Nicoli, Paolo; Calabrese, Chiara; Gaidano, Valentina; Petiti, Jessica; Rosso, Valentina; Signorino, Elisabetta; Carturan, Sonia; Bot-Sartor, Giada; Volpe, Gisella; Frassoni, Francesco; Saglio, Giuseppe; Cilloni, Daniela.

In: Cancer Medicine, Vol. 5, No. 7, 01.07.2016, p. 1650-1653.

Research output: Contribution to journalComment/debate

Gallo, D, Nicoli, P, Calabrese, C, Gaidano, V, Petiti, J, Rosso, V, Signorino, E, Carturan, S, Bot-Sartor, G, Volpe, G, Frassoni, F, Saglio, G & Cilloni, D 2016, 'The Wilms’ tumor (WT1) gene expression correlates with the International Prognostic Scoring System (IPSS) score in patients with myelofibrosis and it is a marker of response to therapy', Cancer Medicine, vol. 5, no. 7, pp. 1650-1653. https://doi.org/10.1002/cam4.735
Gallo, Daniela ; Nicoli, Paolo ; Calabrese, Chiara ; Gaidano, Valentina ; Petiti, Jessica ; Rosso, Valentina ; Signorino, Elisabetta ; Carturan, Sonia ; Bot-Sartor, Giada ; Volpe, Gisella ; Frassoni, Francesco ; Saglio, Giuseppe ; Cilloni, Daniela. / The Wilms’ tumor (WT1) gene expression correlates with the International Prognostic Scoring System (IPSS) score in patients with myelofibrosis and it is a marker of response to therapy. In: Cancer Medicine. 2016 ; Vol. 5, No. 7. pp. 1650-1653.
@article{684494483ffa41d78ee62ab28b8d8c30,
title = "The Wilms’ tumor (WT1) gene expression correlates with the International Prognostic Scoring System (IPSS) score in patients with myelofibrosis and it is a marker of response to therapy",
abstract = "The Wilms tumor gene WT1 is a useful marker of clonal hematopoiesis and it has been shown to be a good marker of residual disease and it reflects the response to therapy. Although myelofibrosis is characterized by mutations of JAK2 and calreticulin (CALR), these mutations are not useful to monitor response to therapy. In this study we demonstrated that in patients affected by myelofibrosis WT1 correlates with the International Prognostic Scoring System (IPSS) score at diagnosis. Furthermore WT1 is a good marker of response to JAK2 inhibitors especially for patients without blasts and for patients who develop anemia or thrombocytopenia not for progression but as therapy related toxicity. Finally, WT1 transcript reduction can mirror a benefit of therapy on the disease burden. This study demonstrated that WT1 is a good marker for monitoring the response to therapy in patients affected by myelofibrosis.",
keywords = "JAK2, molecular marker, myelofibrosis, WT1",
author = "Daniela Gallo and Paolo Nicoli and Chiara Calabrese and Valentina Gaidano and Jessica Petiti and Valentina Rosso and Elisabetta Signorino and Sonia Carturan and Giada Bot-Sartor and Gisella Volpe and Francesco Frassoni and Giuseppe Saglio and Daniela Cilloni",
year = "2016",
month = "7",
day = "1",
doi = "10.1002/cam4.735",
language = "English",
volume = "5",
pages = "1650--1653",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",
number = "7",

}

TY - JOUR

T1 - The Wilms’ tumor (WT1) gene expression correlates with the International Prognostic Scoring System (IPSS) score in patients with myelofibrosis and it is a marker of response to therapy

AU - Gallo, Daniela

AU - Nicoli, Paolo

AU - Calabrese, Chiara

AU - Gaidano, Valentina

AU - Petiti, Jessica

AU - Rosso, Valentina

AU - Signorino, Elisabetta

AU - Carturan, Sonia

AU - Bot-Sartor, Giada

AU - Volpe, Gisella

AU - Frassoni, Francesco

AU - Saglio, Giuseppe

AU - Cilloni, Daniela

PY - 2016/7/1

Y1 - 2016/7/1

N2 - The Wilms tumor gene WT1 is a useful marker of clonal hematopoiesis and it has been shown to be a good marker of residual disease and it reflects the response to therapy. Although myelofibrosis is characterized by mutations of JAK2 and calreticulin (CALR), these mutations are not useful to monitor response to therapy. In this study we demonstrated that in patients affected by myelofibrosis WT1 correlates with the International Prognostic Scoring System (IPSS) score at diagnosis. Furthermore WT1 is a good marker of response to JAK2 inhibitors especially for patients without blasts and for patients who develop anemia or thrombocytopenia not for progression but as therapy related toxicity. Finally, WT1 transcript reduction can mirror a benefit of therapy on the disease burden. This study demonstrated that WT1 is a good marker for monitoring the response to therapy in patients affected by myelofibrosis.

AB - The Wilms tumor gene WT1 is a useful marker of clonal hematopoiesis and it has been shown to be a good marker of residual disease and it reflects the response to therapy. Although myelofibrosis is characterized by mutations of JAK2 and calreticulin (CALR), these mutations are not useful to monitor response to therapy. In this study we demonstrated that in patients affected by myelofibrosis WT1 correlates with the International Prognostic Scoring System (IPSS) score at diagnosis. Furthermore WT1 is a good marker of response to JAK2 inhibitors especially for patients without blasts and for patients who develop anemia or thrombocytopenia not for progression but as therapy related toxicity. Finally, WT1 transcript reduction can mirror a benefit of therapy on the disease burden. This study demonstrated that WT1 is a good marker for monitoring the response to therapy in patients affected by myelofibrosis.

KW - JAK2

KW - molecular marker

KW - myelofibrosis

KW - WT1

UR - http://www.scopus.com/inward/record.url?scp=84991525341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991525341&partnerID=8YFLogxK

U2 - 10.1002/cam4.735

DO - 10.1002/cam4.735

M3 - Comment/debate

VL - 5

SP - 1650

EP - 1653

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

IS - 7

ER -